ReviewKidney diseases (Basel, Switzerland)2024
The Treatment of Coronary Artery Disease in Patients with Chronic Kidney Disease: Gaps, Challenges, and Solutions.
Review in Kidney diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.Current hypertension reports · 2026Review
- Impact of Chronic Kidney Disease on Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions: Insights From Houston Methodist Chronic Total Occlusion Registry.Journal of the American Heart Association · 2026Observational
- Sequential pattern transformer (SPT): a generative and interpretable framework for predicting disease trajectories.Neural computing & applications · 2026Article
- Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study.Cardiorenal medicine · 2026Article
- The impact of chronic kidney disease on the antithrombotic strategies and outcomes in patients with acute coronary syndromes and atrial fibrillation: Insights from STAR-ACS study.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Undiagnosed Coronary Artery Disease in Hemodialysis-Initiating Patients.Journal of atherosclerosis and thrombosis · 2025Article
- Furosemide's Preventative Role in Contrast-Induced Nephropathy among ST-Segment Elevation Myocardial Infarction Patients undergoing Percutaneous Coronary Intervention.Advanced biomedical research · 2025Article
- Coronary Artery Disease in Patients on Dialysis: Impact of Traditional Risk Factors.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Cardiac evaluation in patients awaiting kidney transplant-position statement of the Cardiological Society of India and Indian Society of Nephrology.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is associated with a high burden of coronary artery disease (CAD), which remains the leading cause of death in CKD patients. Despite the high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularization. Summary: The management of CAD is more challenging in patients with CKD than in the general population due to concerns regarding side effects and renal toxicity, as well as uncertainty regarding clinical benefit of guideline-based medical therapy and interventions. Patients with advanced CKD and especially those receiving dialysis have not traditionally been represented in randomized trials evaluating either medical or revascularization therapies. Thus, only scant data from small prospective studies or retrospective analyses are available. Recently published studies suggest that there are significant opportunities to substantially improve both cardiovascular and renal outcomes of patients with CAD and CKD, including new medications and interventions. Thus, the objective of this review is to summarize the current evidence regarding the management of CAD in CKD patients, in particular with respect to improvement of both cardiovascular and renal outcomes. Key Messages: Adequate medical therapy and coronary interventions using evidence-based strategies can improve both cardiac and renal outcomes in patients with CAD and CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.